A phase Ib/IIa trial of panobinostat in combination with trastuzumab in adult female patients with HER2 [human epidermal growth factor receptor 2] positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab.
Phase of Trial: Phase I/II
Latest Information Update: 11 May 2016
At a glance
- Drugs Panobinostat (Primary) ; Panobinostat (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2016 Status changed from completed to discontinued due to insufficient evidence of clinical benefit.
- 24 Mar 2012 Additional location (United Kingdom) added as reported by European Clinical Trials Database record.